This page shows the latest Trophos news and features for those working in and with pharma, biotech and healthcare.
Prior treatment could include olesoxime, an experimental drug Roche acquired as part of its takeover of Trophos three years ago that was abandoned earlier this year after a failed phase 2
Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months”
Will take control of olesoxime for spinal muscular atrophy. . Roche has agreed a 470m deal to buy French pharma company Trophos and its lead drug for the rare neuromuscular disease spinal ... Roche is paying 120m upfront for Marseilles-based Trophos,
Actelion also confirmed it has obtained the option to purchase Trophos, a France-based clinical stage pharmaceutical company, for 10m. ... Trophos has a pipeline of new molecular entities in development for the motor neuron diseases amyotrophic lateral
Agence Nationale pour la Recherche, the French research agency, has awarded Trophos SA a $1.4mn research grant to support drug development. ... Biopharmaceutical company Trophos SA is currently heading a project into the efficacy of candidate drug
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Corporate acquisition. 675. Trophos/Roche. Includes Olesoxime an orphan drug in P2 for spinal muscular atrophy; plus TRO 40303 in P1 for cardiac injury.
A few days later, the acquisition of the French company, Trophos was announced which brings Olesoxime an orphan drug in phase II clinical development for spinal muscular atrophy; plus TRO 40303
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....